CompoAtlas

PMK 007 CVD Heart Power Rebuild

Natural health product licensed in Canada

Other names
CVD Heart Power Rebuild, Heart Health
Licence holder
PMK Federal Regulatory Consultants Ltd.
NPN or DIN-HM
80032809
Status
Active licence
Licence date
14 June 2012
Revision date
Not provided
Form
Capsule
Route of administration
Orale
Application type
Non traditionnelle

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Crataegus laevigata

Source : Fruit

Extraction ratio : 10:1

Dry plant equivalent : 150 milligramme

15 milligrammeNot calculated
L-arginine

Source : Monohydrochlorure de L-arginine

750 milligrammeNot calculated

Non-medicinal ingredients

Cellulose, microcristalline, Eau purifiée, Glycérine, Huile de fève de soja

PopulationAgeQuantity per servingFrequency
AdultesNot specified4 Capsuleminimum: 2 Tous les jours ; maximum: 3 Tous les jours

Uses authorised in Canada

May help support a modest improvement in exercise capacity in individuals with stable cardiovascular diseases (CVD). Used in Herbal Medicine to help reduce elevated blood lipid levels in adults. Used in Herbal Medicine to help reduce hyperlipidaemia in adults. Used in Herbal Medicine to help support cardiovascular health in adults.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Source

Official Health Canada record, licence 80032809

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Crataegus laevigata
    Read the warning, when it applies and the studies cited

    Hawthorn

    Route of administration: Oral (ESCOP 2009; Bradley 2006; Mills and Bone 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking cardiac glycosides (e.g., digoxin) or blood pressure or heart medications (Brinker 2010; Bradley 2006).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have chest pain, irregular heartbeat, or shortness of breath.

    Health Canada monograph dated 31 July 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line